Abstract:Cigarette smoke, a toxic collection of more than 4000 chemicals generated from combustion of tobacco plant leaves, is known to cause several respiratory ailments, including chronic bronchitis, emphysema and lung cancer, and is associated with an increase in respiratory infections. In addition, cigarette smoking is considered a principal aetiological factor responsible for the development of certain diffuse interstitial and bronchiolar lung diseases, namely respiratory bronchiolitis-interstitial lung disease (RB-ILD), desquamative interstitial pneumonia (DIP) and adult pulmonary Langerhans’ cell histiocytosis (PLCH). Although not exclusively seen in cigarette smokers, substantial clinical and epidemiological data support a central role for smoking as the primary causative agent of most RB-ILD, DIP and PLCH. Additional evidence in support of cigarette smoke as a primary aetiological agent in RB-ILD, DIP and PLCH is the observation that smoking cessation may lead to disease improvement, while recurrence of these disorders has been observed to occur in the transplanted lung upon re-exposure to tobacco smoke. Furthermore, histopathological changes of respiratory bronchiolitis, DIP and PLCH (with or without co-existent emphysema) may be found on lung biopsy in the same individual, implicating smoking as a common inciting agent of these diverse lesions. Recent studies also suggest a role for cigarette smoking as a potential co-factor in the development of acute eosinophilic pneumonia, usual interstitial pneumonia and rheumatoid arthritis-associated interstitial lung disease. In the current review, we propose a novel classification that takes into account the complex relationship between cigarette smoking and diffuse lung diseases. Investigation on the role of smoking as a potential causative factor or modifier of these diverse diffuse lung diseases is important, as smoking cessation utilizing state-of-the-art tobacco cessation efforts should be a central part of therapy, while pharmacotherapy with corticosteroids or other immune modifying agents should be reserved for selected patients.

Why making smoking cessation a priority for rare interstitial lung disease smokers?

Smoking-related interstitial lung disease: A narrative review

Smoking-related interstitial lung disease

Interstitial lung diseases: never forget to think about it in primary care

The Role of Lung Microbiome in Fibrotic Interstitial Lung Disease—A Systematic Review

Statement on smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit

Current Challenges and Novel Therapeutic Perspectives

Cigarette Smoking and Diffuse Lung Disease

[Smoking-related interstitial lung disease : Radiological findings, histopathological correlations, and clinical observations]

Rheumatoid arthritis–associated interstitial lung disease: an overview of epidemiology, pathogenesis and management

Risk Factors for Hospital Readmission in Patients with Interstitial Lung Disease

A Systematic Review of the Key Predictors of Progression and Mortality of Rheumatoid Arthritis-Associated Interstitial Lung Disease

Lung Cancer and Interstitial Lung Diseases

Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?

A Practical Multidisciplinary Approach to Identifying Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases: A Clinician's Narrative Review

Pharmacological Treatment of Interstitial Lung Diseases: A Novel Landscape for Inhaled Agents

The far reaching implications of Interstitial Lung Diseases Delayed Diagnosis

Smoking-Related Interstitial Fibrosis (SRIF) in Patients Presenting With Diffuse Parenchymal Lung Disease

Immunomodulatory treatment of interstitial lung disease

Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players

Smoking Cessation: An Integral Part of Lung Cancer Treatment